<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03098589</url>
  </required_header>
  <id_info>
    <org_study_id>NIS-Celgene-JP-PMS-004</org_study_id>
    <nct_id>NCT03098589</nct_id>
  </id_info>
  <brief_title>Revlimid® Capsules Drug Use-results Surveillance (Relapsed or Refractory ATLL)</brief_title>
  <official_title>Revlimid® Capsules Drug Use-results Surveillance Relapsed or Refractory Adult T-cell Leukemia Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Celgene</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Celgene</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To understand the safety and efficacy of Revlimid® Capsules 2.5 mg and 5 mg (hereinafter
      referred to as Revlimid) under actual conditions of use in patients with relapsed or
      refractory adult T-cell leukemia lymphoma (hereinafter referred to as relapsed or refractory
      Adult T-cell Leukemia Lymphoma (ATLL)).

        1. Planned registration period 3 years

        2. Planned surveillance period 4 years and 6 months after a month after the approval for
           partial changes in the approved items is granted for relapsed or refractory ATLL
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 30, 2017</start_date>
  <completion_date type="Anticipated">October 2, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 2, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse Events (AEs)</measure>
    <time_frame>Up to approximately 4 years</time_frame>
    <description>Number of participants with adverse events</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Lymphoma</condition>
  <arm_group>
    <arm_group_label>Patients with T-cell leukemia lymphoma treated with Revlimid</arm_group_label>
    <description>Among patients with relapsed or refractory adult T-cell leukemia lymphoma, patients who received Revlimid will be targeted in this surveillance</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Revlimid</intervention_name>
    <description>Revlimid</description>
    <arm_group_label>Patients with T-cell leukemia lymphoma treated with Revlimid</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Among patients with relapsed or refractory adult T-cell leukemia lymphoma (hereinafter
        referred to as &quot;Adult T-cell Leukemia Lymphoma (ATLL)&quot;) who are treated with Revlimid
        Capsules (hereinafter referred to as &quot;Revlimid&quot;, used by both 2.5 mg and 5 mg capsules).
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - Relapsed or Refractory Adult T-cell Leukemia Lymphoma

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kyoko Matsui, MD</last_name>
    <role>Study Director</role>
    <affiliation>Celgene</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shigeru Minohara, Study manager</last_name>
    <phone>+81-3-5224-0660</phone>
    <email>sminohara@celgene.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>ASO KK Iizuka Hospital</name>
      <address>
        <city>Iizuka</city>
        <state>Fukuoka</state>
        <zip>820-8505</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 28, 2017</study_first_submitted>
  <study_first_submitted_qc>March 28, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 4, 2017</study_first_posted>
  <last_update_submitted>June 7, 2017</last_update_submitted>
  <last_update_submitted_qc>June 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Adult T-cell Leukemia Lymphoma</keyword>
  <keyword>Teratogenicity</keyword>
  <keyword>Myelosuppression</keyword>
  <keyword>Haemorrhage</keyword>
  <keyword>Infection</keyword>
  <keyword>Thromboembolism</keyword>
  <keyword>Hypersensitivity</keyword>
  <keyword>Tumor lysis syndrome</keyword>
  <keyword>Peripheral neuropathy</keyword>
  <keyword>Ischaemic heart disease</keyword>
  <keyword>Cardiac failure</keyword>
  <keyword>Arrhythmia</keyword>
  <keyword>Renal failure</keyword>
  <keyword>Interstitial lung disease</keyword>
  <keyword>Hepatic disorder</keyword>
  <keyword>Hypothyroidism</keyword>
  <keyword>Gastrointestinal perforation</keyword>
  <keyword>Orthostatic hypotension</keyword>
  <keyword>Convulsion</keyword>
  <keyword>Somnolence</keyword>
  <keyword>Confusion</keyword>
  <keyword>Fatigue</keyword>
  <keyword>Dizziness</keyword>
  <keyword>Blurred vision</keyword>
  <keyword>Second primary cancer</keyword>
  <keyword>Cataract</keyword>
  <keyword>Revlimid capsules</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia-Lymphoma, Adult T-Cell</mesh_term>
    <mesh_term>Leukemia, T-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lenalidomide</mesh_term>
    <mesh_term>Thalidomide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

